Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy (Q37774359)

23 August 2017

1 reference

title

Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy (English)

1 reference

23 August 2017

Florian Heitz

1

1 reference

23 August 2017

Philipp Harter

2

1 reference

23 August 2017

Nina Ewald-Riegler

3

1 reference

23 August 2017

Michael Papsdorf

4

1 reference

23 August 2017

Stefan Kommoss

5

1 reference

23 August 2017

Andreas du Bois

6

1 reference

23 August 2017

publication date

1 July 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

7

1 reference

23 August 2017

page(s)

1125-1136

1 reference

Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme

23 August 2017

cites work

1 reference

21 January 2018

1 reference

Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2

21 January 2018

1 reference

Poly(ADP-ribose). The most elaborate metabolite of NAD+.

21 January 2018

1 reference

Structure and function of poly(ADP-ribose) polymerase

21 January 2018

1 reference

The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA.

21 January 2018

1 reference

NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1.

21 January 2018

1 reference

Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?

21 January 2018

1 reference

Reconstructing eukaryotic NAD metabolism

21 January 2018

1 reference

New functions of a long-known molecule

21 January 2018

1 reference

The Involvement of Poly(ADP-ribose) Polymerase in the Degradation of NAD Caused by gamma-Radiation and N-Methyl-N-Nitrosourea

21 January 2018

1 reference

Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells

21 January 2018

1 reference

XRCC1 and DNA strand break repair

21 January 2018

1 reference

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination.

21 January 2018

1 reference

RAD18 and poly(ADP-ribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair.

21 January 2018

1 reference

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways

21 January 2018

1 reference

PARP-1 activation in the ERK signaling pathway

21 January 2018

1 reference

DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation

21 January 2018

1 reference

Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells.

21 January 2018

1 reference

The new life of a centenarian: signalling functions of NAD(P).

21 January 2018

1 reference

Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor

21 January 2018

1 reference

Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.

21 January 2018

1 reference

Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase

21 January 2018

1 reference

Structure/function analysis of PARP-1 in oxidative and nitrosative stress-induced monomeric ADPR formation

21 January 2018

1 reference

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

21 January 2018

1 reference

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy

21 January 2018

1 reference

Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling

21 January 2018

1 reference

Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints

21 January 2018

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

21 January 2018

1 reference

PARsing the phrase "all in for Axin"- Wnt pathway targets in cancer

21 January 2018

1 reference

Wnt/beta-catenin signaling: components, mechanisms, and diseases

21 January 2018

1 reference

Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions

21 January 2018

1 reference

Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks

21 January 2018

1 reference

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

21 January 2018

1 reference

PARP is important for genomic stability but dispensable in apoptosis

21 January 2018

1 reference

Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks

21 January 2018

1 reference

Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance

21 January 2018

1 reference

PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.

21 January 2018

1 reference

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

21 January 2018

1 reference

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

21 January 2018

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers

21 January 2018

1 reference

Breast and ovarian cancer

21 January 2018

1 reference

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

Molecular portraits of human breast tumours

21 January 2018

1 reference

Basal-like breast cancer and the BRCA1 phenotype

21 January 2018

1 reference

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

Reduction of BRCA1 expression in sporadic ovarian cancer

21 January 2018

1 reference

Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

21 January 2018

1 reference

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

21 January 2018

1 reference

Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies

21 January 2018

1 reference

Tenets of PTEN tumor suppression

21 January 2018

1 reference

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

Chemically targeting the PI3K family

21 January 2018

1 reference

Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair

21 January 2018

1 reference

Biallelic mutations in the ATM gene in T-prolymphocytic leukemia

21 January 2018

1 reference

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

21 January 2018

1 reference

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

21 January 2018

1 reference

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

21 January 2018

1 reference

Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways

21 January 2018

1 reference

Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

21 January 2018

1 reference

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.10.53

1 reference

23 August 2017

1 reference